Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2005

View Archived Issues

First milestone in Evotec and Boehringer Ingelheim GPCR collaboration

Medicago and InterveXion establish product codevelopment collaboration

Phase III data show Oracea is effective and safe in patients with rosacea

Immunomodulation induced by NBI-6024 in type 1 diabetic patients

Preclinical data presented on the antidyskinetic effects of sarizotan

Rho kinase inhibition prevents renal and cardiac tissue fibrosis

Pharmacokinetic and pharmacodynamic properties of TRU-015

Connetics to resume Extina development

Phase III study of Erbitux for head and neck cancer meets endpoints

Solvay submits DMF for cell-derived influenza vaccine

IDEA-033 enters new European phase III study

Phase I/IIa trial of BA-210 in acute spinal cord injury recommended to continue

New financing supports Somaxon pipeline development

Altus looks to phase II studies of ALTU-238

FDA Advisory Committee votes on Pulminiq

Protox receives funding to develop lung cancer drug

Merck exercises options to Vical gene delivery technology

Tracleer launched in Japan

Byetta launched for type 2 diabetes

Clinical evidence supports the use of desmoteplase in acute ischemic stroke

New data on the effects of Fibrillex in AA amyloidosis

EP-1572 shows activity as growth hormone secretagogue in healthy volunteers

Recent Icos patents cover novel treatments for fibrotic disorders

Arginine-vasopressin V1b receptor antagonists emerge from Taisho R&D

Novel antiinflammatory/analgesic agents claimed by Bayer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.